Spencer Pharmaceutical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPPH research report →
Price Chart
About the company
Spencer Pharmaceutical Inc. is dedicated to pioneering drug delivery platforms aimed at addressing neurological conditions. A core aspect of their expertise lies in the precise, controlled administration of existing therapeutic compounds for central nervous system disorders, such as Alzheimer's, Parkinson's disease, and various forms of brain cancer.
- CEO
- Maximilien Arella
- IPO
- 2023
- Employees
- 2
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on SPPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.44K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.17%
- ROIC
- 21.49%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $862.54K
- Net Income
- $-862,541+61.5%
- EPS
- $-1.00+66.7%
- OCF Growth
- +71.1%
- FCF Growth
- +71.3%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.69
- RSI (14)
- 20
- Avg Volume
- 3.31K
No earnings-call transcripts are available for SPPH yet.
- Free Float
- 0.0%
- Shares Outstanding
- 294.36M
- Float Shares
- 0
Our SPPH coverage
Recent articles, reports, and earnings notes.
No research on SPPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPPH report →